Global Alliance for Progress

To date (2003 - Dec. 2018),
a total of:
31 countries enrolled in GAP and 37 programs implemented;
31,373 patients with hemophilia, 5,360 with von Willebrand disease (VWD) and 3,819 with rare clotting factor deficiencies have been diagnosed/registered through the GAP Program;
17,853 patients, family members, and national member organization (NMO) board members received training;
26,777 hemophilia treatment centres/healthcare professionals received training;
25 national care programs were established (23 with official commitments/ memorandums of understanding;
6.185 billion IUs cumulative increase in product supply.

The Global Alliance for Progress (GAP) in hemophilia is a 10-year healthcare development project, launched on World Hemophilia Day, April 2003. GAP’s primary goal is to greatly increase the diagnosis and treatment of people with hemophilia, and other bleeding disorders, in 20 targeted developing countries.

The program aims at closing the gap in treatment between developed and developing countries in three key areas: (1) the number of people born with hemophilia and those who reach adulthood; (2) the estimated and actual number of people known with bleeding disorders; and (3) the need versus the availability of treatment products.

The twenty countries selected for the first decade of GAP (2003-2012) include: Algeria, Armenia, Azerbaijan, Belarus, China, Ecuador, Egypt, Georgia, Jordan, Lebanon, Mexico, Moldova, Morocco, Peru, Philippines, Syria, Thailand, Tunisia, Russia, and South Africa.

GAP 2013-2022: the second decade of global development

As part of its 50th anniversary, in 2013, the World Federation of Hemophilia (WFH) initiated a second decade of the GAP Program to actively continue to work on closing the gap in care for people with bleeding disorders in 20 new target countries. The focus is on improving diagnosis for all bleeding disorders, improving treatment in the world’s poorest regions, as well as building on the achievements to date. The overarching goals for the second decade (2013-2022) of GAP will be to:

  • Increase by 50,000 the worldwide number of people identified/diagnosed with a bleeding disorders;
  • Ensure that 50 per cent of those newly diagnosed are from the world’s most impoverished countries.

In order to reach these goals, the WFH has restructured the GAP Program into three tiers of activity:

Tier 1 FULL-GAP PROGRAM: Target new countries to initiate National Care Programs (NCPs) similar to the first decade of GAP;
Tier 2 POST-GAP PROGRAM: Promote continuous improvement to existing NCPs, established in countries that were part of the initial GAP program, and;
Tier 3 MID-LEVEL PROGRAM: Provide support to other targeted mid-tier developed countries that need assistance in moving to the next level of care. 

This will allow a more concerted effort to enhance diagnosis and access to treatment for under-recognized populations, which include people with inhibitors, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders, particularly women with these disorders and carriers.

The GAP Program will also use an enhanced and adapted comprehensive development model developed for the first decade and used by the WFH in all of its NCPs. The WFH model works with the healthcare system, government and social infrastructure of the recipient country, to maximize the use of existing resources and to achieve long-term sustainable development of care and treatment of hemophilia and other bleeding disorders. The implementation of the second decade of the GAP Program will not require countries, under Tiers 2 and 3 of the program, to work simultaneously on all six key areas of bleeding disorders care, outlined in the following model:

Government support
Actively involving the government in allocating resources to hemophilia care

Care delivery
Supporting the structure through which hemophilia services are provided in a country through a network of hemophilia treatment centres

Medical expertise and laboratory diagnosis
Ensuring that medical professionals are well trained and patients are accurately diagnosed

Treatment products
Helping to enhance the supply of safe treatment products

Patient organization
Providing coaching on effective management, public relations skills, fundraising, advocacy, and patient education

Data Collection & Outcomes Research
Helping to gather evidence needed to make the case for better care

As with the first decade, the GAP Program will also include the development of educational tools and training guides that will reach out to the entire bleeding disorders community. Several other countries are accessing GAP information on the WFH website to implement their own development projects, by using the tools and models developed by the WFH.

Duration and phases
Current GAP countries
Comprehensive development model (PDF)

Articles about GAP

For more information about GAP, contact us at

Updated April 2019

The WFH GAP Program is supported by funding from:

Visionary Partners

Leadership Partners

Collaborating Partners

The WFH would like to thank the World Health Organization for its support of the GAP Program.